

To: PETER MAC CANCER CENTRE  
ST ANDREWS PL  
EAST MELBOURNE  
VIC 3002

**Patient:** A. Patient  
**URN:**  
**DOB:** 01-Jan-2000  
**SEX:** U  
**Location:**

**Requester:** Which Doctor

**Sample:** 14K3838  
**Ext Ref:**  
**Collected:** 01-Jan-2000  
**Received:** 01-Jan-2000  
**Specimen:**  
**Block ID:**

## CANCER PANEL REPORT

### Results

**No activating or inactivating mutations were detected.**

### Interpretation

A negative result in this assay reflects the limited sensitivity of the TruSeq Amplicon Cancer Panel to the rare genomic changes associated with many cancers.

### Method

Tumour DNA is analysed using the xxxx Cancer Panel.

This mutation panel is designed to detect xxx. The variants detected by this assay should be confirmed by a second method before being used to guide clinical decisions.

### Comments

DNA extraction of this tissue sample produced sufficient good quality material for testing. Sample processing passed all expected QC metrics and high quality sequence with high coverage (0 mean aligned reads/amplicon) and uniformity (0 % amplicons >0.2 mean aligned reads) was obtained.

Please contact the laboratory on xxxx if you wish to discuss this report further.

**This test has not yet been fully validated to the current NPAAC requirements for an in-house IVD and results should be interpreted accordingly. All findings should be confirmed by an independent clinical assay. For further information, please contact the laboratory.**

Reported by:

Authorised by:

Reported: 20-Jan-2016 6:05 PM

Low quality amplicons: